Key clinical point: Targeted prophylaxis with posaconazole was effective in children with acute lymphoblastic leukemia undergoing induction chemotherapy.

Major finding: Posaconazole prophylaxis reduced the odds of invasive fungal infections by greater than 60% and prolonged infection-free survival significantly.

Study details: A single-center, retrospective cohort study of invasive fungal infection in 155 patients with newly diagnosed acute lymphoblastic leukemia.

Disclosures: The authors reported that they had no conflicts of interest.